Premium
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome
Author(s) -
Visentin Andrea,
Imbergamo Silvia,
Scomazzon Edoardo,
Pravato Stefano,
Frezzato Federica,
Bonaldi Laura,
Pizzi Marco,
Vio Stefania,
Gregianin Michele,
Burei Marta,
Facco Monica,
Semenzato Gianpietro,
Piazza Francesco,
Trentin Livio
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15440
Subject(s) - ibrutinib , idelalisib , breakpoint cluster region , bruton's tyrosine kinase , cancer research , medicine , tyrosine kinase , leukemia , receptor , chronic lymphocytic leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom